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78 The Journal of Thoracic and Cardiobjective: Improvements in ventricular function after cellular cardiomyoplasty
ppear to be limited by the poor survival of the cellular implants. Angiogenic
retreatment of infarcted myocardium may improve implanted cell survival and
onsequently myocardial function.
ethods: Fischer 344 rats underwent coronary artery ligation and injection of an
denovirus encoding vascular endothelial growth factor 121 or of saline solution at
ncreasing intervals after ligation. Myocardial perfusion and mass preservation were
ssessed. On the basis of these data, four groups of animals underwent coronary
igation and adenovirus with or without syngeneic skeletal myoblast administration:
1) adenovirus at ligation and myoblasts 3 weeks later (n  7), (2) saline solution
t ligation and myoblasts 3 weeks later (n  8), (3) saline solution at ligation and
weeks later (n  8), and (4) saline solution at ligation and adenovirus with
yoblasts 3 weeks later (n  5). Left ventricular ejection fraction was analyzed by
chocardiography before coronary ligation and 3 and 5 weeks later, after which cell
urvival was assessed in harvested tissues.
esults: Myocardial infarct perfusion was at least 50% greater in animals treated
ith adenoviral vector than with saline solution immediately after ligation (P 
02). In comparison, delayed adenovirus administration did not significantly dimin-
sh infarct perfusion but resulted in decreased myocardial preservation (P  .05).
ccordingly, adenovirus administration nearly tripled implanted myoblast survival
elative to saline solution–treated animals (P  .004). Left ventricular ejection
raction was improved, however, only after cell implantation with adenovirus
retreatment (P  .027).
onclusion: Angiogenic strategies can help to preserve myocardium jeopardized by
cute coronary occlusions. Angiogenic pretreatment enhances the efficacy of cel-
ular cardiomyoplasty.
espite progress during the last several decades in the treatment of
coronary atherosclerosis, coronary artery disease remains the leading
cause of death worldwide, resulting in approximately 7 million deaths
ach year. More specifically, the delayed treatment of acute coronary occlusion
nd consequent myocardial infarction typically lead to myocardial dysfunction
vascular Surgery ● February 2007
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ETnd, potentially, congestive heart failure—the leading
ause of death from coronary artery disease.
Although myocardial injury has conventionally been
onsidered to be irreversible beyond 6 hours after acute
oronary occlusion, data from a number of percutaneous
oronary intervention trials suggests that delayed reopening
f occluded coronary vasculature may lead to the preserva-
ion of myocardial function and improved long-term cardi-
c-related prognosis.1 Such beneficial results are thought to
e related to salvage of the ischemic border zone surround-
ng the central area of infarction, which may also progress
o infarction depending on the adequacy of perfusion to
hese regions.
Therapeutic angiogenesis describes the strategy of ad-
inistering angiogenic growth factors or other mediators to
nhance the tissue of ischemic tissues, typically when an
ccluded arterial vasculature can not be reopened though
onventional strategies.2-4 Although much remains un-
nown regarding the optimal administration of angiogenic
gents, angiogenic strategies have already been applied with
ome success experimentally and clinically in enhancing the
unction of ischemic but viable myocardium. In contrast,
ngiogenic strategies would be expected to be less effective
n improving the function of already infarcted myocardium.
he implantation of myogenic or undifferentiated stem cells
cellular cardiomyoplasty) has been demonstrated in a num-
er of animal and early clinical trials to effect salvage of
uch areas of myocardial infarction.4-16
A major limitation of cellular cardiomyoplasty tech-
iques has been the poor survival (10%) of cellular im-
lants.14-17 We have surmised that cellular implant loss may
e related to the relatively ischemic environment of the
nfarct tissue, and we and others have demonstrated that
retreatment with angiogenic mediators improves implanted
ell survival and consequent physiologic outcomes.17,18 In
ontrast, others have advocated the concurrent administra-
ion of cells and angiogenic agents.19-22
We analyzed the interval for administering angiogenic
reatment after an acute coronary occlusion necessary to
dequately salvage myocardium. With these data, we dem-
nstrated that angiogenic pretreatment of infarcted myocar-
Abbreviations and Acronyms
AdVEGF adenovirus encoding vascular endothelial
growth factor
CSI  cell survival index
LVEF  left ventricular ejection fraction
PBS  phosphate-buffered saline solution
T0  time 0, coronary ligation and pretreatment
time
T1  time 1, 3 weeks after coronary ligationium before skeletal myoblast implantation, as opposed to m
The Journal of Thoracicimultaneous angiogenic treatment and cell implantation, is
ritical for enhancing ventricular function.
ethods
odel Preparation and Vector Administration
dult male Fischer 344 rats (275-300 g; Harlan Sprague Daw-
ey, Inc, Indianapolis, Ind), treated in accordance with protocols
pproved by the Evanston Northwestern Healthcare Institu-
ional Animal Care and Use Committee, were anesthetized with
ntraperitoneally administered ketamine and xylazine (85 and
2 mg/kg body weight, respectively), intubated, and placed on
rodent ventilator (Harvard Instruments, Holliston, Mass). A
eft fourth intercostal space thoracotomy was then performed,
nd the left coronary artery was found and ligated 1 to 2 mm
rom its origin. At the same time, five uniformly distributed
0-L injections each containing 2.0  109 particle units of
eplication-defective adenovirus encoding the 121–amino acid
soform of vascular endothelial growth factor (AdVEGF),23 an
qual volume of phosphate-buffered saline solution (PBS), or
o injections (n  8 per group) were administered into the area
f myocardium subtended by the ligated coronary artery,
eadily identifiable as an area of blanching on the anterolateral
spect of the left ventricle. The thoracotomy was then closed in
ayers, and the animal was allowed to recover under supervi-
ion. Rethoracotomy was performed 2 or 7 days later, and
elayed vector or PBS administration was performed
nalogously.
vans Blue Perfusion Analysis
nimals were killed by pentobarbital overdose (150 mg/kg) 21
ays after coronary ligation, and the heart was excised. The as-
ending aorta was cannulated and perfused with 15 mL Evans blue
ye (Sigma, St Louis, Mo) in PBS (0.25 mg/mL).24 The infarct
egion, which was readily delineated by the gross absence of blue
taining, was resected from the stained left ventricle with a Leica
issection microscope (Leica Microsystems Heidelberg GmbH,
annheim, Germany). The wet weight of the excised segments
as measured, and the epicardial surface area was determined with
etamorph software (Universal Imaging, Downingtown, Pa). The
nfarcted myocardium was then homogenized in PBS and ex-
racted with formamide at 60°C. Evans blue content was then
easured in the supernatant of each sample at 578 nm, as previ-
usly described.24
icrosphere Analysis
n separate confirmatory experiments, rats treated as described
ere subjected to thoracotomy 21 days after ligation for mi-
rosphere perfusion analysis (n  5 per group). An aliquot of
 106 red fluorescent polystyrene microspheres (15 m
iameter; Molecular Probes, Inc, Eugene, Ore) in 1 mL PBS
as injected directly into the left atrium. After 15 minutes, the
nimal was killed and the heart was excised. The thinned infarct
egion was identified grossly and excised under a dissection
icroscope, as previously described.7 After wet weights and
nfarct surface areas were measured, microsphere content in
ach infarct sample was determined in triplicate according to
anufacturer recommendations.
and Cardiovascular Surgery ● Volume 133, Number 2 479
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4
ETistologic Evaluation
n another set of animals treated as described here, whole hearts
ere excised and then fixed with zinc-formalin before paraffin
mbedding. Sections were taken from the ventricular apex to
he base at 500-m intervals with a 10-m thickness and
repared for histochemical staining with hematoxylin and eosin
Sigma).
solation of Transgenic Myoblasts
keletal myoblasts were harvested from adult syngeneic Fischer
44 rats expressing the gene encoding for human alkaline phos-
hatase. (Transgenic rats were a gift from E. Sandgren, University
f Wisconsin.)25 Briefly, 0.5 mL of 0.5% bupivacaine (Abbott
aboratories, Abbott Park, Ill) was injected in the rat hind limbs,
nd skeletal muscle biopsy specimens (approximately 1 cm3) taken
2 hours later were minced and digested with trypsin 0.025%
thylenediaminetetraacetic acid (Gibco BRL, Carlsbad, Calif) and
ollagenase type II (Worthington Biochemical Corporation, Lake-
ood, NJ). Primary harvests were expanded on laminin-coated
Gibco) plates (equivalent to 1  108 cells after 7 days) and
assaged before confluence. The cultured cells were 95% to 99%
iable (by trypan blue exclusion) and approximately 85% pure
fluorescein isothiocyanate–labeled desmin monoclonal antibody).
ells were distributed into freezing media and stored (1.5  106
ells/vial).
yoblast Preparation
tored myoblasts were thawed and collected in PBS (1 mL)
mmediately before myocardial administration. Cells used for sur-
ival studies were treated with a 1-mol/L solution of Hoechst
3342 (Sigma) and incubated at 37°C in 5% carbon dioxide for 15
inutes. The cells were subjected to three washes in PBS at 5
imes the initial media volume and then allowed to recover for 45
inutes in Ham F12 media. The cells were re-suspended in 100
L PBS. An aliquot of 1  106 red fluorescent 2.0-m micro-
pheres (Molecular Probes) was added to each cell injectate as
n internal delivery and sampling standard.17 Cells used for
unctional and echocardiographic studies were likewise pre-
ared, except without the addition of Hoechst 33342 or
icrospheres.
yoblast Administration Studies
he human alkaline phosphatase–negative rats underwent initial
oronary ligation and adenoviral vector or PBS administration at
ime 0 (T0), followed by myoblast administration through a retho-
acotomy 3 weeks later (T1), as follows: group 1 (n  7) received
dVEGF at coronary ligation (T0) and myoblasts 3 weeks later
T1); group 2 (n  8) received PBS at T0 and myoblasts at T1;
roup 3 (n  8) received PBS at T0 and T1; and group 4 (n  5)
eceived PBS at T0 and AdVEGF with myoblasts at T1. The
yoblast aliquot or PBS was administered as five equidistant
ubepicardial 20-L injections throughout the infarcted myocar-
ium, which was identified as a grayish-white area on the antero-
ateral surface of the left ventricle (approximately 20%-30% of the
eft ventricle). The thoracotomy was then closed, and the animals
ere allowed to recover. t
80 The Journal of Thoracic and Cardiovascular Surgery ● Februnctional Assessment by Echocardiography
chocardiographic analysis was performed at three points: before
oronary ligation, 3 weeks after ligation (T1), and 5 weeks after
igation (2 weeks after cell implantation). Left ventricular ejection
raction (LVEF) was measured from apical end-systolic and end-
iastolic points in the 2-dimensional echocardiographic long-axis
iew with a 14-MHz pediatric probe (Acuson Corporation, Moun-
ain View, Calif). All measurements were performed off-line by
sing the cineloop feature to retrospectively visualize the beating
eart at the maximal end-diastolic and end-systolic volumes re-
uired for endocardial area tracing (leading edge method). Final
nalysis included the averaged measurements of three consecutive
ardiac cycles per animal by an experienced observer (B.S.)
linded to the treatment groups.
ell Survival Analysis
nimals were killed 2 weeks after cell implantation. The hearts
ere then harvested, and myocardial tissues were analyzed for
ellular implant survival as previously described.17 A cell survival
ndex (CSI) was calculated as the ratio of blue-stained nuclei
cellular implants) divided by the total number of red microspheres
control for injectate delivery and tissue sampling) in five separate
elds per animal. A mean CSI was calculated from these measure-
ents for each animal.
tatistical Analysis
ata are expressed as means  SD. Two-sided Fisher exact test or
nalysis of variance was used to show significance. Post hoc tests
ith Bonferroni correction were used for pairwise comparisons.
esults
erfusion Analyses
nfarct perfusion was significantly greater in animals that
eceived AdVEGF rather than PBS immediately after liga-
igure 1. Myocardial infarct perfusion. Perfusion is depicted by
vans blue concentration in region of myocardial infarction 21
ays after coronary ligation as function of interval between
oronary ligation and adenoviral vector (VEGF) versus saline
ehicle (PBS) administration.ion, as demonstrated by Evans blue uptake in the region of
uary 2007
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ETnfarction (180  30 g/mg tissue vs 120  20 g/mg
issue, respectively, P  .003) and by microsphere perfu-
ion studies (14  2 spheres/mg tissue vs 8  3 spheres/mg
issue, P  .016). AdVEGF administration delayed until 7
ays after ligation did not significantly alter infarct perfu-
ion (Figure 1) but did result in decreased myocardial mass
reservation (Figure 2). This did not appear to be related to
hanges in infarct area (Figure 3) but did appear to be
ssociated with myocyte preservation and prevention of
brosis, rather than increased myocardial edema (Figure 4).
ellular Implant Survival
n contrast to our expectations, regardless of whether Ad-
EGF was administered as pretreatment 3 weeks before cell
mplantation (group 1) or concurrently with cell implanta-
ion (group 4), the (implanted) CSI was increased relative to
he PBS-treated control group (group 2; CSI 1.9  0.7 and
.6  0.6 vs 0.7  0.4, respectively; P  .004). Histologic
igure 2. Myocardial infarct mass. Infarct wet weight measured
1 days after coronary ligation is depicted as function of interval
etween coronary ligation and adenoviral vector (VEGF) versus
aline vehicle (PBS) administration as either absolute weight
ivided by area of infarct (A) or relative (percentage) difference in
nfarct mass (B).nalysis of implanted tissues clearly found human alkaline i
The Journal of Thoracichosphatase–positive cells in the infarcted myocardium at
ensities consistent with CSI determinations (Figure E1).
chocardiography
VEF was similar in all experimental groups at T0 imme-
iately before coronary ligation and at T1 3 weeks later
Figure 5). LVEF decreased by approximately 33% during
his interval, consistent with a large area of anterolateral
yocardial thinning noted by echocardiographic imaging
Figure E2).
LVEF was significantly improved 2 weeks after cell im-
lantation in (pretreated) group 1 relative to (control) groups 2
hrough 4 (P  .0003). LVEF 2 weeks after cell implantation
pproached baseline values for group 1 (62% 14%) and was
ignificantly greater than values in control groups 2 through
(38%  10%, 49%  19%, and 42%  9% respectively,
 .027). Finally, whereas 5 of 7 group 1 animals (71%)
emonstrated an improvement in LVEF, improvements
ere seen in only 1 of 8 group 2 animals (13%), 1 of 8
roup 3 animals (13%), and 2 of 5 group 4 animals (40%,
 .047 for group 1 vs groups 2 and 3 and P  .04 for
roup 1 vs group 4; Figure E3).
iscussion
n this study, we demonstrated that salvage of myocardial
unction appears to be optimized if angiogenic treatment is
elivered soon after an acute coronary occlusion and if
ngiogenic pretreatment of myocardium is provided before
ell implantation. In contrast to our previous studies involv-
ng fetal cardiomyocyte implants,17 the functional benefit of
his pretreatment strategy was not directly correlated with
igure 3. Myocardial infarct area. Infarct area measured 21 days
fter coronary ligation is depicted as function of interval between
oronary ligation and adenoviral vector (VEGF) versus saline
ehicle (PBS) administration.mproved survival of (skeletal myoblast) implants.
and Cardiovascular Surgery ● Volume 133, Number 2 481
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4
ETSeveral alternative strategies have previously been re-
orted to improve the survival of cells implanted into re-
ions of myocardial infarction, including the ex vivo trans-
ection of these cells with angiogenic mediators, the
imultaneous administration of cells and angiogenic agents,
nd the endowment of cellular implants with antiapoptotic
roperties though ex vivo transfection.18-22,26 Although it is
ot yet clear whether any of these approaches will ulti-
ately yield superior cell survival benefits, and although the
echanisms whereby cell implantation enhances cardiac
unction remain controversial (autocrine and paracrine bio-
ogic activities vs passive geometric and compliance prop-
rties vs contractile contributions), it is notable that im-
roved cell survival appears fairly consistently to improve
he outcomes of cellular cardiomyoplasty.8,14-22,26,27
It is conceivable that the effectiveness of various implant
urvival strategies may be a function of the susceptibility of the
espective implants to ischemia and the robustness or rapidity
f effect of these survival strategies. For example, it is possible
hat the apparent inconsistency in terms of cell survival be-
ween this study and our previous study may be related to the
elative sturdiness of myoblasts versus fetal cardiomyocytes. In
his regard, it is conceivable that although myoblasts are suf-
ciently resistant to ischemia to survive in the infarct milieu,
hey may nevertheless survive only in a state of functional
ibernation, failing to contribute significantly to improved
verall left ventricular function. Enhanced ventricular function
ith AdVEGF pretreatment could therefore be the result of thenterval provided for angiogenesis and increased infarct perfu- p
82 The Journal of Thoracic and Cardiovascular Surgery ● Febrion to develop and thereby support enhanced (implanted) cell
unction in group 1 relative to the simultaneous treatment
roup 4 in this study. It can not be ruled out, however, that the
ntiapoptotic effects of vascular endothelial growth factor may
lso underlie these observations.
The clinical use of skeletal myoblasts has been discour-
ged in part because of data from initial clinical trials
emonstrating increased incidence of ventricular arrhyth-
ias after skeletal myoblast implantation, presumably on
he basis of the electrical isolation of these cells from the
ost myocardium.28 Subsequent clinical data have not con-
rmed these observations.29,30 Further, it is not clear that
ny candidate cell type will electrically integrate into the
ost myocardium such that potentially arrhythmogenic re-
ntrant circuits can be avoided. If skeletal myoblasts possess
uperior survivability characteristics, then these cells may
et prove to be an important cardiomyoplasty candidate.
tudy Limitations
his report does not address the possibility that the im-
rovement in LVEF seen in (pretreatment) group 1 relative
o (concurrent treatment) group 4 is simply the result of a
reater time allowance for the development of angiogenesis
n the former versus the latter group (5 vs 2 weeks, respec-
ively), irrelevant to the implantation of cells. An AdVEGF-
lone group would have been needed to rule out this pos-
ibility; numerous previous studies, however, including our
revious work in the same model, tend to discount this
Figure 4. Morphology of myocardial
scar as function of various treatments.
(A) Saline vehicle administration at
time of coronary ligation (day 0); (B)
adenoviral vector administration at
time of coronary ligation (day 0); (C)
saline vehicle administration 7 days
after coronary ligation; (D) adenoviral
vector administration 7 days after cor-
onary ligation. LV, Left ventricle.remise.17-20
uary 2007
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ETAnother potential concern regarding these findings is in
egard to our failure to detect a significant difference in
VEF with myoblast implantation relative to untreated,
igated controls. In this regard, previously reported im-
rovements in LVEF in animal models have generally been
elatively small (absolute change in LVEF 10%) although
tatistically significant. Although the failure to detect such
hanges with echocardiography in our small animal model
ay be considered a limitation of this study and may be
elated to the fairly large variability in the (no treatment)
ontrol group 3, our differentiation of the effects of an-
iogenic pretreatment from the control groups overall
nd as depicted in the same-animal improvement trends
ith pretreatment (Figure E3) can alternatively be
iewed as highlighting the potential robustness of the
retreatment strategy.
Another limitation of this study was our use of staining
echniques to assess implanted cell survival. An alternative
pproach would have been to use quantitative polymerase
hain reaction assay to determine the number of surviving
ells. However, we were unable to complete such studies.
he previously validated staining assays17 ultimately used
n this study represent a reasonable if cumbersome
lternative.
Finally, we cannot rule out the possibility that the re-
orted mass preservation reported after early postligation
ascular endothelial growth factor treatment is related to
hanges in myocardial water content conferred by the vas-
igure 5. Mean left ventricular (LV) ejection fraction (EF), as
etermined by echocardiographic analysis. Group 1 (n  7) rep-
esents adenoviral vector at coronary ligation, myoblasts 3 weeks
ater. Group 2 (n  8) represents saline vehicle at coronary
igation, myoblasts 3 weeks later. Group 3 (n  8) represents
aline vehicle at coronary ligation and 3 weeks later. Group 4
n  5) represents saline vehicle at coronary ligation, adenoviral
ector with myoblasts 3 weeks later. T0, Time of coronary liga-
ion; T1, 3 weeks after coronary ligation; T2, 5 weeks after
oronary ligation.ular endothelial growth factor transgene, unrelated to myo-
The Journal of Thoracicyte survival. Qualitative histologic analyses, however, sug-
est that this is not the case. Similarly, differences in tissue
eight were observed at least 14 days after vector admin-
stration, well after any adenovirus-mediated gene expres-
ion effects would be expected to have subsided.
onclusions
n conclusion, these studies support a role for angiogenic
alvage of infarcting myocardium and for angiogenic pre-
reatment in enhancing the efficacy of cellular cardiomyo-
lasty, probably as a result of myocardial scar revascular-
zation that supports the function of cellular implants in the
nfarct milieu. Theoretically, such angiogenic and cellular
herapies could be administered in the setting of completed
nfarctions, early after the acute interval in which myocar-
ial infarction is likely to occur, or in circumstances in
hich percutaneous coronary intervention results in the
o-reflow phenomenon.
We thank B. Cushing for help in preparation of the manuscript.
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ETFigure E1. Photomicrograph demonstrating human alkaline phosphatase–positive myoblasts treated with Elf 97
substrate (Invitrogen, Carlsbad, Calif) indicative of donor cells.
Figure E2. Two-dimensional echocardiographic images confirm preservation of left ventricular mass in (left)
adenovirus-pretreated animals relative to (right) saline-pretreated animals. Arrow depicts anteroapical region
receiving cell administration.The Journal of Thoracic and Cardiovascular Surgery ● Volume 133, Number 2 484.e1
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ETFigure E3. Improvements in ejection fraction in individual subjects at time of cell implantation (Pre Cell) versus
2 weeks later (Post Cell). Group 1 (n  7) represents adenoviral vector at coronary ligation, myoblasts 3 weeks
later. Group 2 (n  8) represents saline vehicle at coronary ligation, myoblasts 3 weeks later. Group 3 (n  8)
represents saline vehicle at coronary ligation and 3 weeks later. Group 4 (n  5) represents saline vehicle at
coronary ligation, adenoviral vector with myoblasts 3 weeks later. P  .04 for group 1 versus groups 2 and 3.84.e2 The Journal of Thoracic and Cardiovascular Surgery ● February 2007
